We reasoned that, as cytokines in vivo will be rapidly washed away, MIP-1 β might be bound to endothelial surfaces and so induce adhesion in its immobilized form.

Our data indicate that cytokines are among the many proteins that bind to endothelial surfaces in a GAG-dependent fashion.

Recent developments have shown that there are different endothelial surfaces in tumors which has led to the concept of endothelial cell adhesion molecule mediated targeted drug delivery to tumors.

This complex interacts with fibrinogen and thus plays an important role in platelet aggregation and adhesion to endothelial surfaces.

When this occurs, the coagulation factors are no longer carboxylated at certain glutamic acid residues, and are incapable of binding to the endothelial surface of blood vessels, and are thus biologically inactive.

Its major physiologic role appears to be neutralization of heparin-like molecules on the endothelial surface of blood vessels, thereby inhibiting local antithrombin III activity and promoting coagulation.

Activated leukocytes release these inflammatory mediators during inflammation, inhibiting the creation of both thrombomodulin and EPCR, and inducing their shedding from the endothelial surface.

This damaged endothelial surface inhibits anticoagulant properties as well as increases antifibrinolysis, which can lead to intravascular clotting, microvascular thrombosis and multiple organ failure.

This receptor binds weakly to carbohydrate ligands on leukocyte surfaces and causes them to "roll" along the endothelial surface as bonds are made and broken.

The vesicles are located on the endothelial surface.